TABLE OF CONTENTS
1 INTRODUCTION 84
1.1 OBJECTIVES OF THE STUDY 84
1.2 MARKET DEFINITION 84
1.3 OVERVIEW OF THE NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET 84
1.4 CURRENCY AND PRICING 86
1.5 LIMITATIONS 87
1.6 MARKETS COVERED 87
2 MARKET SEGMENTATION 91
2.1 MARKETS COVERED 91
2.2 GEOGRAPHICAL SCOPE 92
2.3 YEARS CONSIDERED FOR THE STUDY 93
2.4 DBMR TRIPOD DATA VALIDATION MODEL 94
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
2.6 MULTIVARIATE MODELLING 98
2.7 MARKET APPLICATION COVERAGE GRID 99
2.8 TEST TYPE LIFELINE CURVE 100
2.9 DBMR MARKET POSITION GRID 101
2.10 VENDOR SHARE ANALYSIS 102
2.11 SECONDARY SOURCES 103
2.12 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHTS 107
4.1 PESTEL ANALYSIS 108
4.2 PORTER'S 5 FORCES 109
4.3 EPIDEMIOLOGY 110
4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 111
4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 111
5 INDUSTRY INSIGHTS 112
6 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 114
7 MARKET OVERVIEW 117
7.1 DRIVERS 119
7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 119
7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 121
7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 122
7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 122
7.2 RESTRAINTS 123
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 123
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 124
7.3 OPPORTUNITIES 124
7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 124
7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 125
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 125
7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 126
7.4 CHALLENGES 126
7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 126
7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 127
8 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 128
8.1 OVERVIEW 129
8.2 IMAGING 133
8.2.1 COMPUTED TOMOGRAPHY 134
8.2.2 ULTRASOUND 134
8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 134
8.2.4 ANGIOGRAPHY 134
8.2.5 X-RAY 134
8.2.6 OTHERS 134
8.3 BLOOD TEST 134
8.4 BIOPSY 135
8.4.1 FINE NEEDLE ASPIRATION 136
8.4.2 NEEDLE CORE BIOPSY 136
8.5 BIOMARKER TEST 136
8.5.1 AQUAPORIN 1 (AQP1) 138
8.5.2 PERILIPIN (PLIN2) 138
8.5.3 N-METHYLTRANSFERASE (NMNT) 138
8.5.4 L-PLASTIN (LCP-1) 138
8.5.5 NM23A 138
8.6 GENETIC TEST 138
8.7 OTHERS 139
9 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 141
9.1 OVERVIEW 142
9.2 STAGE I 145
9.3 STAGE II 145
9.4 STAGE III 146
9.5 STAGE IV 147
10 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 148
10.1 OVERVIEW 149
10.2 RENAL CELL CARCINOMA 153
10.2.1 IMAGING 154
10.2.2 BLOOD TEST 154
10.2.3 BIOPSY 154
10.2.4 BIOMARKER TEST 154
10.2.5 GENETIC TEST 154
10.2.6 OTHERS 154
10.3 CLEAR CELL RENAL CELL CARCINOMA 154
10.3.1 IMAGING 156
10.3.2 BLOOD TEST 156
10.3.3 BIOPSY 156
10.3.4 BIOMARKER TEST 156
10.3.5 GENETIC TEST 156
10.3.6 OTHERS 156
10.4 NON CLEAR CELL RENAL CELL CARCINOMA 156
10.4.1 PAPILLARY RENAL CELL CARCINOMA 157
10.4.1.1 IMAGING 158
10.4.1.2 BLOOD TEST 158
10.4.1.3 BIOPSY 158
10.4.1.4 BIOMARKER TEST 158
10.4.1.5 GENETIC TEST 158
10.4.1.6 OTHERS 158
10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 158
10.4.2.1 IMAGING 159
10.4.2.2 BLOOD TEST 159
10.4.2.3 BIOPSY 159
10.4.2.4 BIOMARKER TEST 159
10.4.2.5 GENETIC TEST 159
10.4.2.6 OTHERS 159
11 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 160
11.1 OVERVIEW 161
11.2 INSTRUMENT BASED PRODUCTS 165
11.2.1 IMAGING 166
11.2.2 BIOPSY 166
11.3 PLATFORM BASED PRODUCTS 166
11.3.1 NEXT GENERATION SEQUENCING 168
11.3.2 MICROARRAYS 168
11.3.3 PCR 169
11.3.4 OTHERS 169
11.4 KITS AND REAGENTS 169
11.4.1 RENAL CANCER PANELS 171
11.4.2 RENAL CANCER ANTIBODIES 171
11.5 OTHER CONSUMABLES 171
12 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 172
12.1 OVERVIEW 173
12.2 FLUORESCENT IN SITU HYBRIDIZATION 176
12.3 NEXT GENERATION SEQUENCING 176
12.4 FLUORIMMUNOASSAY 177
12.5 COMPARATIVE GENOMIC HYBRIDIZATION 178
12.6 IMMUNOHISTOCHEMICAL 179
12.7 OTHERS 179
13 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 181
13.1 OVERVIEW 182
13.2 SCREENING 185
13.2.1 INSTRUMENT BASED PRODUCTS 186
13.2.2 PLATFORM BASED PRODUCTS 186
13.2.3 KITS AND REAGENTS 186
13.2.4 OTHER CONSUMABLES 186
13.3 DIAGNOSTIC AND PREDICTIVE 186
13.3.1 INSTRUMENT BASED PRODUCTS 187
13.3.2 PLATFORM BASED PRODUCTS 187
13.3.3 KITS AND REAGENTS 187
13.3.4 OTHER CONSUMABLES 187
13.4 PROGNOSTIC 188
13.4.1 INSTRUMENT BASED PRODUCTS 189
13.4.2 PLATFORM BASED PRODUCTS 189
13.4.3 KITS AND REAGENTS 189
13.4.4 OTHER CONSUMABLES 189
13.5 RESEARCH 189
13.5.1 INSTRUMENT BASED PRODUCTS 190
13.5.2 PLATFORM BASED PRODUCTS 190
13.5.3 KITS AND REAGENTS 190
13.5.4 OTHER CONSUMABLES 191
14 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 192
14.1 OVERVIEW 193
14.2 HOSPITALS 196
14.3 DIAGNOSTIC CENTERS 196
14.4 CANCER RESEARCH CENTERS 197
14.5 ACADEMIC INSTITUTES 198
14.6 AMBULATORY SURGICAL CENTERS 198
14.7 OTHERS 199
15 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 200
15.1 OVERVIEW 201
15.2 DIRECT TENDER 204
15.3 RETAIL SALES 204
15.4 OTHERS 205
16 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 206
16.1 NORTH AMERICA 207
16.1.1 U.S. 221
16.1.2 CANADA 230
16.1.3 MEXICO 239
17 NORTH AMERICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 248
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 248
18 SWOT ANALYSIS 249
19 COMPANY PROFILE 250
19.1 CANON MEDICAL SYSTEMS CORPORATION 250
19.1.1 COMPANY SNAPSHOT 250
19.1.2 REVENUE ANALYSIS 250
19.1.3 COMPANY PROFILE 251
19.1.4 PRODUCT PORTFOLIO 251
19.1.5 RECENT DEVELOPMENT 251
19.2 KONINKLIJKE PHILIPS N.V. 252
19.2.1 COMPANY SNAPSHOT 252
19.2.2 REVENUE ANALYSIS 252
19.2.3 COMPANY PROFILE 253
19.2.4 PRODUCT PORTFOLIO 253
19.2.5 RECENT DEVELOPMENTS 254
19.3 GENERAL ELECTRIC COMPANY 255
19.3.1 COMPANY SNAPSHOT 255
19.3.2 REVENUE ANALYSIS 255
19.3.3 COMPANY PROFILE 256
19.3.4 PRODUCT PORTFOLIO 256
19.3.5 RECENT DEVELOPMENTS 257
19.4 SIEMENS HEALTHCARE GMBH 258
19.4.1 COMPANY SNAPSHOT 258
19.4.2 REVENUE ANALYSIS 258
19.4.3 COMPANY PROFILE 259
19.4.4 PRODUCT PORTFOLIO 259
19.4.5 RECENT DEVELOPMENT 260
19.5 GRAIL 261
19.5.1 COMPANY SNAPSHOT 261
19.5.2 PRODUCT PORTFOLIO 261
19.5.3 RECENT DEVELOPMENTS 261
19.6 AMBRY GENETICS 263
19.6.1 COMPANY SNAPSHOT 263
19.6.2 PRODUCT PORTFOLIO 263
19.6.3 RECENT DEVELOPMENT 263
19.7 BIOVENDOR R&D 264
19.7.1 COMPANY SNAPSHOT 264
19.7.2 PRODUCT PORTFOLIO 264
19.7.3 RECENT DEVELOPMENT 264
19.8 BLUEPRINT GENETICS OY. 265
19.8.1 COMPANY SNAPSHOT 265
19.8.2 PRODUCT PORTFOLIO 265
19.8.3 RECENT DEVELOPMENT 265
19.9 CD GENOMICS 266
19.9.1 COMPANY SNAPSHOT 266
19.9.2 PRODUCT PORTFOLIO 266
19.9.3 RECENT DEVELOPMENT 266
19.10 CENTOGENE N.V. 267
19.10.1 COMPANY SNAPSHOT 267
19.10.2 REVENUE ANALYSIS 267
19.10.3 PRODUCT PORTFOLIO 268
19.10.4 RECENT DEVELOPMENT 268
19.11 CREATIVE DIAGNOSTICS 269
19.11.1 COMPANY SNAPSHOT 269
19.11.2 PRODUCT PORTFOLIO 269
19.11.3 RECENT DEVELOPMENT 269
19.12 FUJIFILM CORPORATION 270
19.12.1 COMPANY SNAPSHOT 270
19.12.2 REVENUE ANALYSIS 270
19.12.3 PRODUCT PORTFOLIO 271
19.12.4 RECENT DEVELOPMENTS 271
19.13 GENEDX, LLC 272
19.13.1 COMPANY SNAPSHOT 272
19.13.2 REVENUE ANALYSIS 272
19.13.3 PRODUCT PORTFOLIO 273
19.13.4 RECENT DEVELOPMENT 273
19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY 274
19.14.1 COMPANY SNAPSHOT 274
19.14.2 PRODUCT PORTFOLIO 274
19.14.3 RECENT DEVELOPMENT 274
19.15 ILLUMINA, INC. 275
19.15.1 COMPANY SNAPSHOT 275
19.15.2 REVENUE ANALYSIS 275
19.15.3 PRODUCT PORTFOLIO 276
19.15.4 RECENT DEVELOPMENT 276

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.